TAP vs TSHA · rev $13.04B vs $640.7M cap
TAP (TAP) versus Taysha Gene Therapies Inc (TSHA) — a side-by-side from cached financials, not a winner call.
TAP (TAP) common stock.
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
Latest reported TAP revenue for 2025-12-31 was $13.04B. Net income was -$2.14B. Revenue was down 5.1% from 2024-12-31 to 2025-12-31. TAP currently screens at market cap $0.
Latest reported TSHA revenue for 2026-06-30 was $0. Net income was -$89.0M. TSHA currently screens at market cap $640.7M.
TAP currently screens at market cap $0. TSHA currently screens at market cap $640.7M.
Not investment advice. Open the TAP and TSHA stock pages for the full models.
Not investment advice.